Compare e l f Beauty Inc (ELF) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Novo Nordisk A/S — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.25B), while Novo Nordisk A/S trades at $38.21 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 26.4× e l f Beauty Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Novo Nordisk A/S for 116 Days on average.
| ELF | NVO | |
|---|---|---|
Market Cap | $6.25B | $165.31B |
Volume | 1,099,552 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $63.98 |
52-Week Low | $49.57 | $35.29 |
Typical Hold Time | 25 Days | 116 Days |
Enterprise Value | $6.84B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
